当前位置: 首页 >> 检索结果
1. The WORKWELL programme: a randomized controlled trial of job retention vocational rehabilitation for people with inflammatory arthritis.
作者: Alison Hammond.;Jennifer Parker.;Sarah Cotterill.;Chris Sutton.;Selman Mirza.;Angela Ching.;Terence W O'Neill.;Fiona Holland.;Antonia Marsden.;Paula Holland.;Kathryn Radford.;Suzanne M M Verstappen.;Martin Eden.;Garima Dalal.;Simone Battista.;June Culley.;Karen Walker-Bone.;Sarah Woodbridge.;Rachel O-Brien.;Yvonne Hough.;Yeliz Prior.
来源: Rheumatology (Oxford). 2026年65卷8期
People with inflammatory arthritis (InfA) frequently experience work instability, absenteeism, and reduced productivity, culminating in early job loss. This study evaluated the effectiveness and cost-effectiveness of WORKWELL job retention vocational rehabilitation (JRVR) delivered by occupational therapists, compared with a control group receiving written self-help advice.
2. Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST.
作者: Laura C Coates.;Dafna D Gladman.;Joseph F Merola.;Ulrich Mrowietz.;April Armstrong.;Xenofon Baraliakos.;William Tillett.;Mitsumasa Kishimoto.;Jyotsna Reddy.;Lichen Teng.;Hamid Amouzadeh.;Cynthia Deignan.;Philip J Mease.;Laure Gossec.
来源: Rheumatology (Oxford). 2026年65卷7期
Data regarding progression from oligoarticular to polyarticular psoriatic arthritis (PsA) are sparse. Using FOREMOST, we identify progression predictors and evaluate apremilast's treatment effect in early PsA.
3. Personalized, physiotherapist-guided exercise programs in JIA: home-based vs. immersive virtual reality (JiaFitXR).
作者: Nilay Arman.;Asya Albayrak.;İrem Dönmez.;Yusuf Açıkgöz.;Asena Yekdaneh.;Figen Çakmak.;Betül Sözeri.;Nuray Aktay Ayaz.
来源: Rheumatology (Oxford). 2026年65卷7期
To compare the effects of two physiotherapist-guided, personalized, stepwise-adapted exercise interventions-a home-based program (HomeEX) and an immersive virtual reality (IVR) exergaming program (JiaFitXR)-on physical fitness, functional capacity and physical activity in adolescents with Juvenile Idiopathic Arthritis (JIA).
4. Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trial.
作者: Gabriele De Marco.;Walter P Maksymowych.;Mikkel Østergaard.;Iris Eshed.;Ai Lyn Tan.;Philip S Helliwell.;Dennis McGonagle.;Elizabeth M A Hensor.;Helena Marzo-Ortega.
来源: Rheumatology (Oxford). 2026年65卷7期
To describe the prevalence and extent of whole body (WB)-MRI detected joint disease features and their response to therapy in patients with early, active PsA.
5. Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.
作者: Laure Gossec.;Laura C Coates.;Robert B M Landewé.;Philip J Mease.;Joseph F Merola.;Christopher T Ritchlin.;Yoshiya Tanaka.;Akihiko Asahina.;Fabian Proft.;Nadine Goldammer.;Myriam Manente.;Barbara Ink.;Rajan Bajracharya.;Jason Coarse.;Iain B McInnes.
来源: Rheumatology (Oxford). 2026年65卷5期
Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has demonstrated tolerability and clinical efficacy in patients with PsA. Here, we report an additional year of safety and efficacy of bimekizumab treatment to 3 years.
6. A randomised open-label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-Pilot).
作者: Christopher P Denton.;Philip Yee.;Medha Kanitkar.;Hannah Sims.;Charlotte Clarke.;Saiam Ahmed.;Voon H Ong.;Francesco Del Galdo.;John D Pauling.;Marina E Anderson.;Muditha Samaranayaka.;Michael Hughes.;Smita Bhat.;Bridget Griffiths.;Maya H Buch.;Ariane L Herrick.;David D'Cruz.;Madelon C Vonk.;Nick Freemantle.;Hakim-Moulay Dehbi.
来源: Rheumatology (Oxford). 2026年65卷3期
Mycophenolate mofetil (MMF) is routinely used in early diffuse cutaneous systemic sclerosis (dcSSc) but not in limited cutaneous (lc)SSc. This may miss an opportunity to slow disease progression. MINIMISE-Pilot tested the feasibility of an open-label event-driven randomised trial of MMF vs no immunosuppression in lcSSc.
7. Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomized, controlled, open-label, non-inferiority trial.
作者: Francisco J Blanco.;Laura Galindo.;Belen Acasuso.;Vanesa Balboa-Barreiro.;Juan D Cañete.;Benjamin Fernández-Gutiérrez.;Isidoro González-Álvaro.;José Luis Pablos Álvarez.;Carmen Bejerano-Herrería.;Maite Silva-Díaz.;Ignacio Rego-Perez.;Lucia Lourido.;Cristina Ruiz-Romero.;Miren Uriarte-Ecenarro.;Rosario García-Vicuña.;Andrea Cuervo.;Julio Ramírez.;Raquel Celis.;Luis Rodríguez-Rodríguez.;Lydia Abasolo Alcázar.;Dalifer Freites Nuñez.;Maria Martín-López.;Francisco J Toro-Santos.;Natividad Oreiro.
来源: Rheumatology (Oxford). 2026年65卷3期
The aim of this study was to identify robust predictive markers which may help personalize tapering protocols, minimizing flare risk while optimizing long-term disease management in RA patients.
8. Transcutaneous auricular vagus nerve stimulation versus sham stimulation in patients with erosive hand osteoarthritis (ESTIVAL): a randomised, multicentre, double-blind, sham-controlled trial.
作者: Alice Courties.;Sophie Tuffet.;Grégoire Cormier.;Christian H Roux.;Paul Ornetti.;Yves-Marie Pers.;Jacques-Éric Gottenberg.;Eric Lespessailles.;Roland Chapurlat.;Denis Arniaud.;François Rannou.;Daniel Wendling.;Florent Eymard.;Sylvain Mathieu.;Pascal Richette.;Alain Saraux.;Hubert Marotte.;Nicolas Poursac.;Anne-Christine Rat.;Jean-Philippe Bastard.;Soraya Fellahi.;Yves Henrotin.;Lise Minssen.;Camille Deprouw.;Christelle Nguyen.;Amel Touati.;Laurence Bérard.;Alexandra Rousseau.;Tabassome Simon.;Emmanuel Maheu.;Francis Berenbaum.;Jérémie Sellam.
来源: Lancet Rheumatol. 2026年8卷2期e98-e107页
Erosive hand osteoarthritis is a painful and inflammatory disease without effective treatments. In this study we aimed to investigate the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) compared with sham stimulation in patients with inflammatory erosive hand osteoarthritis.
9. Assessing clinical and cost effectiveness of total versus partial knee replacement (TOPKAT): 10-year follow-up of a multicentre, randomised controlled trial.
作者: David J Beard.;Loretta J Davies.;Jonathan A Cook.;Graeme MacLennan.;Jemma Hudson.;Andrew J Price.;Andrew J Carr.;Matthew Little.;Jose Leal.;Ray Fitzpatrick.;David W Murray.;Marion K Campbell.; .
来源: Lancet Rheumatol. 2026年8卷2期e116-e126页
The Total or Partial Knee Arthroplasty Trial (TOPKAT) aimed to evaluate the difference between total knee replacement (TKR) and partial (unicompartmental) replacement (PKR) for treatment of late-stage medial compartment knee osteoarthritis. As longevity is a key issue for joint replacement, extended follow-up periods are required to fully evaluate the long-term efficacy. In this analysis, we report the 10-year follow-up of the TOPKAT trial.
10. Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.
作者: Ming-Hui Zhao.;Fidencio Cons Molina.;Gustavo Aroca.;Maria G Tektonidou.;Anubhav Mathur.;Radhika Tangadpalli.;Rui Sun.;Ruvie Martin.;Pascale Pellet.;Thao Ngoc Phuong Huynh.
来源: Rheumatology (Oxford). 2026年65卷1期
The objective of this study was to evaluate the efficacy and safety of s.c. secukinumab 300 mg combined with standard of care (SoC) in adult patients with active LN.
11. Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years.
作者: Philip J Mease.;Laura C Coates.;Corine Gaillez.;Alexis Shew.;Weibin Bao.;Christopher T Ritchlin.
来源: Rheumatology (Oxford). 2026年65卷1期
To examine relationships between radiographic progression and achievement of low disease activity (LDA) or remission at week 104 in patients with PsA receiving secukinumab.
12. Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis.
作者: Helena Marzo-Ortega.;Iain B McInnes.;Mohamed Sharaf.;Alen Zabotti.;Emmanouil Rampakakis.;Dennis McGonagle.;Ahmed Abogamal.;Pascal Richette.;Georg Schett.
来源: Rheumatology (Oxford). 2026年65卷1期
To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR).
13. Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.
作者: Gabriele De Marco.;Elizabeth M A Hensor.;Philip S Helliwell.;Shabina Sultan.;Sayam R Dubash.;Xabier Michelena.;Laura C Coates.;Paul Emery.;Ai Lyn Tan.;Dennis McGonagle.;Helena Marzo-Ortega.
来源: Lancet Rheumatol. 2025年7卷11期e776-e788页
The optimal treatment strategy in early psoriatic arthritis remains unknown. We aimed to assess whether the combination of methotrexate and golimumab plus corticosteroids is superior to methotrexate plus corticosteroids in reducing disease activity in early, untreated psoriatic arthritis.
14. Personalised gait retraining for medial compartment knee osteoarthritis: a randomised controlled trial.
作者: Scott D Uhlrich.;Valentina Mazzoli.;Amy Silder.;Andrea K Finlay.;Feliks Kogan.;Garry E Gold.;Scott L Delp.;Gary S Beaupre.;Julie A Kolesar.
来源: Lancet Rheumatol. 2025年7卷10期e708-e718页
Retraining individuals with medial compartment knee osteoarthritis to walk with a patient-specific change in their foot angle (ie, toe-in or toe-out angle) can reduce excessive joint loading related to disease progression. This study investigated the clinical, biomechanical, and structural efficacy of personalised foot progression angle modifications compared with sham treatment in patients with mild-to-moderate medial compartment knee osteoarthritis.
15. Clinical and cost-effectiveness of a cycling and education intervention versus usual physiotherapy care for the treatment of hip osteoarthritis in the UK (CLEAT): a pragmatic, randomised, controlled trial.
作者: Thomas W Wainwright.;Tikki Immins.;Sharon Docherty.;Geoff Saunders.;Annie Hawton.;Elizabeth Goodwin.;Tim Rees.;Matthew Low.;Jo Samways.;Fran Webley.;Nikki Howard.;Paul H Lee.;Robert G Middleton.
来源: Lancet Rheumatol. 2025年7卷11期e764-e775页
Osteoarthritis of the hip is a leading cause of chronic disability. The cycling and education intervention (CLEAT) trial aimed to compare the clinical and cost-effectiveness of the cycling against hip pain (CHAIN) intervention, a group-based cycling and education programme, with usual physiotherapy care for patients with hip osteoarthritis referred for physiotherapy at a UK hospital.
16. Individualizing NSAID therapy in axial spondyloarthritis: N-of-1 trials with Bayesian analysis.
作者: Mark C Hwang.;Seokhun Kim.;Shervin Assassi.;Reyna Chavez.;Joyce Samuel.;Charles Green.;Jon Tyson.;John Reveille.
来源: Rheumatology (Oxford). 2025年64卷12期6114-6121页
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly affecting the spine and sacroiliac joints. NSAIDs are first-line therapy, but individual responses vary widely. We evaluated the efficacy and patient preference of three NSAIDs (celecoxib, meloxicam and naproxen) through Bayesian N-of-1 clinical trials to optimize axSpA management.
17. An educational tool to improve PREeclamPsia knowledge and Aspirin adheRence in lupus prEgnancies: the PREPARE trial.
作者: Joo-Young Esther Lee.;Arielle Mendel.;Isabelle Malhamé.;Megan R W Barber.;Ann E Clarke.;Paul R Fortin.;John G Hanly.;Alexandra Legge.;Christine Peschken.;Carl A Laskin.;Zahi Touma.;Murray B Urowitz.;Sasha Bernatsky.;Évelyne Vinet.
来源: Rheumatology (Oxford). 2025年64卷11期5707-5715页
To evaluate the effect of an educational tool on preeclampsia knowledge, as well as aspirin (ASA) use and adherence in pregnant SLE women.
18. Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study.
作者: Andreas Hess.;Koray Tascilar.;Hanna M Schenker.;Laura Konerth.;Verena Schönau.;Marina Sergeeva.;Silke Kreitz.;Jutta Prade.;Sandra Strobelt.;Mageshwar Selvakumar.;Arnd Kleyer.;Matthias Englbrecht.;Axel J Hueber.;Mario M Zaiss.;Eugen Feist.;Gerd R Burmester.;Reinhard E Voll.;Stephanie Finzel.;Christoph Baerwald.;Julie Rösch.;Frank Behrens.;Michaela Koehm.;Jose Antonio P da Silva.;Nemanja Damjanov.;Arnd Dörfler.;Georg Schett.;Jürgen Rech.
来源: Lancet Rheumatol. 2025年7卷8期e565-e575页
Rheumatoid arthritis is an inflammatory disease frequently treated with TNF inhibitors. Little is known about predictors of response to TNF inhibitors. Because clinical response in rheumatoid arthritis is measured by composite scores containing subjective patient-orientated domains (eg, pain and global disease perception), we hypothesised that patients with high disease representation in the CNS might respond better to TNF inhibitors than patients with less CNS disease representation.
19. Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab.
作者: Koji Suzuki.;Hideto Kameda.;Kei Ikeda.;Tomonori Ishii.;Kosaku Murakami.;Hyota Takamatsu.;Yoshiya Tanaka.;Takayuki Abe.;Tsutomu Takeuchi.;Yuko Kaneko.
来源: Rheumatology (Oxford). 2025年64卷11期5948-5957页
To predict the efficacy of IL-6 inhibition in patients with Still's disease by analysing inflammatory cytokine profiles before and during an IL-6 receptor inhibitor therapy.
20. Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.
作者: Amir Jamaludin.;Rhydian Windsor.;Sarim Ather.;Timor Kadir.;Andrew Zisserman.;Juergen Braun.;Lianne S Gensler.;Mikkel Østergaard.;Denis Poddubnyy.;Thibaud Coroller.;Brian Porter.;Gregory Ligozio.;Aimee Readie.;Pedro M Machado.
来源: Rheumatology (Oxford). 2025年64卷10期5446-5454页
To evaluate the performance of machine learning (ML) models for the automated scoring of spinal MRI bone marrow oedema (BMO) in patients with axial spondyloarthritis (axSpA) and compare them with expert scoring.
|